NATIONAL ACADEMIES Sciences Engineering Medicine

The Evidence Base for Lyme Infection-Associated Chronic Illnesses Treatment

Speaker Biographies

Wendy Adams, M.B.A.
Research Grant Director, Bay Area Lyme Foundation

Wendy Adams joined Bay Area Lyme, a leading public 501c3 organization, at its founding in 2012, and played a key role in developing its strategy to make Lyme disease easy to diagnose and simple to cure. As Research Grant Director and a member of the Advisory Board, she leads Bay Area Lyme's scientific research grantmaking strategy and represents the voice of patients to government advisory committees and agencies including HHS, CDC, and NIH. Wendy is also an active member of the Board of Directors for the Lyme Disease Biobank, a leading source of well characterized patient samples to enable diagnostic development for tick-borne infections. Wendy's unique perspective and knowledge as a former Lyme patient—as well as her background in product development and business strategy in the healthcare industry—make her skillset valuable to BAL. She has spent over 20 years in the biotechnology industry, and while recovering from tick-borne infections, she ran B2DC LLC, a business development consultancy for biotech clients in infectious and autoimmune disease, therapeutic and prophylactic vaccines, oncology, drug delivery, and neurology companies. She served as a member or subcommittee member of the HHS Tick-Borne Disease Working Group Federal Advisory Committee from 2017-2020 and currently serves as a Programmatic Reviewer for the Department of Defense Congressionally Directed Medical Research Program in Tick-Borne Disease. She also serves on the Lyme Disease Advisory Committee for the California Department of Public Health and has served as a technical advisor to CDC on the Lyme disease vaccine currently in clinical trials. Wendy holds an MBA from the Haas School of Business, University of California at Berkeley, where she also served on the faculty in Entrepreneurship, and an AB from Duke University.

John Aucott, M.D.
Director, Johns Hopkins Lyme Disease Clinical Research Center; Associate Professor of Medicine, Johns Hopkins University

Dr. Aucott has been involved in care of patients and research in Lyme disease since joining the Johns Hopkins faculty in 1996. He assumed the position of Director of the Johns Hopkins Lyme Disease Research Center in April 2015 and is an Associate Professor of Medicine at the Johns Hopkins University School of Medicine, Division of Rheumatology. In 2023, he became the inaugural recipient of the Barbara Townsend Cromwell Professor in Lyme Disease and Tick-borne Illness. Dr. Aucott’s research is focused on improved diagnostic testing and health related outcomes in Lyme disease. He is widely recognized an international expert in post-treatment Lyme disease. He is currently the Principal Investigator for the SLICE studies, examining the impact of Lyme disease on health outcomes and the human immune system. The well-characterized biorepository of blood samples from the SLICE studies are a nationally recognized resource that has formed the basis of numerous collaborations studying the microbiology and immune pathophysiology of Lyme disease. The SLICE biorepository has been instrumental in the development of several new candidate diagnostic tests for Lyme disease. Dr. Aucott received his undergraduate degree in molecular biology from the University of California at Berkeley and his MD from the Johns Hopkins University School of Medicine. He trained at University Hospitals

of Cleveland and is a diplomate of the American Board of Internal Medicine with board certification in Infectious Diseases.

C. Benjamin (Ben) Beard, Ph.D.
Deputy Division Director, Division of Vector-Borne Diseases, CDC

Charles Benjamin (Ben) Beard is the Principal Deputy Director of CDC's Division of Vector-Borne Diseases. He also serves as co-chair of CDC's Climate and Health Taskforce and served previously as the CDC's representative to the U.S. Department of Health and Human Services' Tick-Borne Disease Working Group. He has served outside CDC on numerous working groups and advisory panels for the World Health Organization, the Bill & Melinda Gates Foundation, the U.S. Global Change Research Program (USGCRP), the National Academies of Sciences, Engineering and Medicine, and the American Meteorological Society. He served as an editor and lead author for the USGCRP Climate Change and Human Health Group 2016 report, The Impacts of Climate Change on Human Health in the United States: A Scientific Assessment, and he was an author on the Human Health Chapter of the 2023 USGCRP Fifth National Climate Assessment. He is an Associate Editor for Emerging Infectious Diseases and past president of the Society for Vector Ecology. During his tenure at the CDC, his work has focused on the ecology, prevention, and control of vector-borne zoonotic diseases, both in domestic and global arenas, including serving as Deputy Incident Manager for CDC's 2016 Zika Virus Outbreak Response, for CDC's 2023 Domestic Malaria Response, and for CDC's 2024 Dengue Response. He has published over 150 scientific papers, books or book chapters, and commissioned reports collectively.

Charles Chiu, M.D., Ph.D.
Professor of Laboratory Medicine and Medicine, University of California, San Francisco

Charles Chiu is Professor of Laboratory Medicine and Medicine, Division of Infectious Diseases at University of California, San Francisco and Director of the UCSF Clinical Microbiology Laboratory. Chiu currently leads a translational research laboratory focused on the development and clinical validation of metagenomic next-generation sequencing (mNGS) and host response profiling assays for diagnosis of infections, outbreak investigation, and pathogen discovery. He is a principal developer of a CRISPR-Cas12a based assay for the diagnosis of COVID-19, for which FDA Emergency Use Authorization was obtained in July of 2020, and has achieved FDA breakthrough device designation for mNGS assays for pathogen identification from cerebrospinal and respiratory fluids. Chiu also leverages machine learning based approaches to develop host response classification models based on RNA gene expression for differential diagnosis of central nervous system infections, infection-associated chronic illnesses (Lyme disease, chronic fatigue syndrome, and long COVID), and hyperinflammatory syndromes such as sepsis and multi-systm inflammatory syndrome in children (MIS-C). Chiu's work is supported by funding from the National Institutes of Health (NIH), US Center for Disease Control and Prevention (CDC), Biomedical Advanced Research and Development Authority (BARDA), Abbott Laboratories, Chan-Zuckerberg Biohub, the Steven and Alexandra Cohen Foundation, and the California Initiative to Advance Precision Medicine. Dr. Chiu has authored more than 200 peer-reviewed publications, holds over 15 patents and patent applications, is a co-founder of Delve Bio, and serves on the scientific advisory board of Delve Bio, Biomeme, Mammoth Biosciences, Flightpath Biosciences, Biomesense, and Poppy Health.

Daniel (Dan) Clauw, M.D.
Professor of Anesthesiology, Internal Medicine (Rheumatology), and Psychiatry; Director, Chronic Pain and Fatigue Research Center, University of Michigan

Daniel Clauw is a Professor of Anesthesiology, Medicine (Rheumatology) and Psychiatry at the University of Michigan. He serves as Director of the Chronic Pain and Fatigue Research Center. Until January 2009 he also served as the first Associate Dean for Clinical and Translational Research within the University of Michigan

Medical School, and PI of the UM Clinical and Translational Sciences Award (CTSA). He attended the University of Michigan for both undergraduate and medical school studies and then completed his Internal Medicine residency and Rheumatology Fellowship at Georgetown University. He joined the faculty at Georgetown University in 1990, and while there, founded the Georgetown Chronic Pain and Fatigue Research Center, and served as the Division Chief of Rheumatology, Immunology and Allergy, and Vice Chair of the Department of Medicine. Since moving to UM in 2001, Dr. Clauw has continued his commitment to the clinical care and research into overlapping conditions such as Fibromyalgia, Gulf War Illnesses, and Interstitial Cystitis just to name a few, having become an internationally known expert in chronic pain, and especially the central nervous system contributions to chronic pain states, performing past or ongoing work in conditions such as low back pain, osteoarthritis, vulvodynia, endometriosis, irritable bowel syndrome, and temporomandibular joint disorder.

Elliot P. Cowan, Ph.D.
Founder & Principal, Partners in Diagnostics

Dr. Elliot Cowan is Principal and Founder, in 2013, of Partners in Diagnostics, LLC, providing consulting on the regulation of in vitro diagnostics to IVD manufacturers, as well as to international public health agencies, procurement organizations, regulatory harmonization efforts, governmental bodies, and philanthropic foundations. This followed a 20-year career at the US Food and Drug Administration, where he was responsible for leading the regulation of all blood donor screening tests and retroviral diagnostics used in the US, including the first over-the-counter HIV test system, approved in 2012. Elliot was also a member of the Laboratory Technical Working Group for the President's Emergency Plan for AIDS Relief (PEPFAR), providing technical assistance for laboratory quality assurance issues in PEPFAR focus countries, and advised the World Health Organization on the development and restructuring of its Prequalification of Diagnostics Programme, and has helped to build regulatory systems for IVDs in Sub-Saharan Africa. Elliot received a BA from Williams College and a PhD in Biology and Biomedical Sciences from Washington University in St. Louis.

Raymond (Ray) Dattwyler, M.D.
Professor of Pathology, Microbiology and Immunology, Medicine, and Pediatrics, New York Medical College

Dr. Dattwyler activities both at Stony Brook and at New York Medical College have focused on the laboratory diagnosis, treatment and prevention of vector borne infectious disease. He was the director Lyme disease and tick-borne disease center at Stony Brook for approximately 20 years. In that role, Dr. Dattwyler was responsible for much of the clinical care of patients with Lyme disease. His group at Stony Brook carried out many of the key studies on the antibiotic treatment of Lyme disease that defined the use of doxycycline, ceftriaxone, amoxicillin and investigated a number of other antibiotics. Dr. Dattwyler has had a strong interest in the laboratory diagnosis of infectious diseases in general and specifically for tick borne infections. Over the course of his research career, he has worked toward the development of and improvement in diagnostic assays, especially for Lyme disease. We have carried out epitope mapping of the major antigens of Borrelia burgdorferi and have applied these research findings to the development of improved immunodiagnostics. Dr. Dattwyler has served on multiple committees and study sections for the NIH, FDA, CDC, and DOD. This includes the CDC committee that establish the guidelines for laboratory diagnosis of Lyme disease.

Rachele Hendricks-Sturrup, D.H.Sc., M.Sc., M.A.
Director, Real-World Evidence, Duke-Margolis Institute for Health Policy

Dr. Rachele Hendricks-Sturrup is the Research Director of Real-World Evidence (RWE) at the Duke-Margolis Institute for Health Policy in Washington, DC, strategically leading and managing the Institute's RWE Collaborative and RWE policy research portfolio and education. As an engagement expert, biomedical researcher, bioethicist, and policy practitioner with over 18 years of experience, her work centers on addressing

implementation, regulatory, and ethical, legal, and social implications (ELSI) at the intersection of health policy and innovation.

Liz Horn, Ph.D., M.B.I.
Principal Investigator, Lyme Disease Biobank

Liz serves as PI of Lyme Disease Biobank, a resource created to provide much-needed blood, urine, and tissue samples to researchers studying Lyme disease and other tick-borne infections. More than 1250 participants (representing early Lyme, later stages of Lyme, persistent Lyme, and controls) have been enrolled. Each participant's sample donation can support up to 50 different research projects. Currently, 100+ projects in academia and industry have been approved for samples. Liz earned her doctorate in molecular pharmacology and cancer therapeutics from SUNY at Buffalo, was a National Library of Medicine fellow in biomedical informatics and received her MBI from Oregon Health & Science University. She has spent 2 decades working with non-profit organizations to build research initiatives and collaborations with academia, other non-profits, and industry. Liz is passionate about building resources to move research forward that help people, improve lives, and reduce suffering.

Stacie Hudgens, M.A.
Chief Executive Officer and Strategic Lead Regulatory & Access, Clinical Outcomes Solutions

Stacie is Chief Executive Officer and Strategic Lead at Clinical Outcomes Solutions. She has over 20 years of research experience, specializing in research design and statistical and psychometric analysis with extensive US and European Regulatory submissions and presentations including participation on the FDA's Study Endpoints and Label Development group's Mixed Methods Panel. She brings 13 years of experience in clinical trials and health and economic outcomes research and 4 years of experience in educational measurement and has developed webinars and symposiums on mixed methods including small sample size psychometric and statistical methodologies. Stacie's experience in health economics and outcomes research includes psychometrics, clinical and observational research design, item development and validation, patient-reported outcomes (PROs) in clinical trials, economic modeling, secondary data analysis, and longitudinal and missing data analysis. In addition, she specializes in development of health economic and outcomes studies for regulatory and commercial consideration. Stacie has worked and published extensively in multiple disease states, with extensive expertise in oncology and diabetes, and has worked cross-functionally with regulatory, biostatistics, and marketing groups to inform and support PRO measurement strategies in product development. Prior to her position at Adelphi Values, Stacie held dual roles as the PRO, statistical and psychometric expert as well as leading the Internal Studies team of a large pharmaceutical company, in the area of Global Health Economics and Outcomes Research. Previously, Stacie held an Adjunct Faculty position at the Chicago School of Professional Psychology where she taught Research Methods, Introduction and Advanced Statistics.

Beth Jaworski, Ph.D.
Director of Participant Platforms, All of Us *Research Program, National Institutes of Health*

Dr. Jaworski joined the Office of Behavioral and Social Sciences Research (OBSSR) at the National Institutes of Health (NIH) as a social and behavioral sciences administrator in September 2021. In this role, she supports the OBSSR mission to enhance the impact of health-related behavioral and social sciences research, coordinate and integrate these sciences within the larger NIH research enterprise, and communicate health-related behavioral and social sciences research findings. Beth earned her Ph.D. in social psychology from the University of California, Santa Cruz and her bachelor's degree in psychology from the University of Wisconsin–Madison. Prior to joining

OBSSR, she served as the mobile user experience (UX) lead at the Veteran Affairs' National Center for Post-Traumatic Stress Disorder (PTSD), Dissemination and Training Division, where she split her time between creating and researching public mental health apps for PTSD and related conditions. Dr. Jaworski's research interests are focused on how the social and behavioral sciences can be leveraged to design and implement impactful and engaging digital health interventions. She is especially interested in mixed-methods approaches that center health equity and inclusion, take social context into account, and explore innovative ways to deliver and integrate health information across a range of settings. She earned her Ph.D. in social psychology from the University of California, Santa Cruz and her bachelor's degree in psychology from the University of Wisconsin, Madison.

Lorraine Johnson, J.D., M.B.A.
Chief Executive Officer, LymeDisease.org

Lorraine is the Chief Executive Officer of LymeDisease.org and the Principal Investigator of its patient registry and research platform, MyLymeData. She is regarded as a subject matter expert on patient engagement, data privacy, big data research, patient registries, and Lyme disease. She has authored over 50 peer reviewed publications on Lyme disease and patient-centered healthcare, including five big data studies for which she served as Principal Investigator. She is an author of two college text book chapters on patient engagement, big data and patient registries. She has served on several federal advisory committees related to big data, patient centered research, and patient registries including the inaugural Patient Engagement Advisory Panel for the Patient Centered Outcomes Research Institute (PCORI), both the Steering Committee and the Executive Committee of its big data project, PCORnet, and chair of its Patient Council on data privacy. She participated in the White House Precision Medicine Summit. She sat on the Steering Committee of Consumers United for Evidence Based Healthcare, and has presented extensively at professional, medical, and governmental conferences including the Cochrane Colloquium (Plenary Session), the American Association for the Advancement of Science, the NIH Collaboratory, the NIH Science of Team Science Conference, PCORnet, and the Society to Improve Diagnosis in Medicine.

Nancy Klimas, M.D.
Director, Institute for Neuro-Immune Medicine; Professor of Medicine, Nova Southeastern University

Dr. Klimas has 40 years of professional experience and has achieved international recognition for her research and clinical efforts in multi-symptom disorders, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Gulf War illness (GWI), fibromyalgia, and most recently Long COVID. She is the Director of the Institute for Neuro-Immune Medicine, Assistant Dean of Research and Professor of Clinical Immunology at the Dr. Kiran C. Patel College of Osteopathic Medicine. She chairs the Department of Clinical Immunology at Nova Southeastern University. Dr. Klimas is Professor Emerita, at the University of Miami's Miller School of Medicine where she practiced for 30 years, a diplomat of the American Board of Internal Medicine, a diplomat in Diagnostic Laboratory Immunology, and Director of Environmental Medicine Research at the Miami Veterans Affairs Medical Center Geriatric Research Education and Clinical Center (GRECC). She has achieved national and international recognition for her research and clinical efforts in multi-symptom disorders, including ME/CFS and GWI. She is a past president of the International Association for ME/CFS and a past member of the Health and Human Services CFS Advisory Committee., the VA GWI Research Advisory Committee, the National Academy of Medicine's ME/CFS clinical case definition working group, and has served on several NIH advisory panels. She founded the NSU Institute for Neuro Immune Medicine, where she directs a group of eighteen remarkable interdisciplinary scientists and clinicians who are working together from bedside to bench and back to bedside, working to discover and implement innovative strategies that effectively treat or prevent these disabling chronic illnesses, while training the next generation of clinicians and scientists.

John Leong, M.D., Ph.D.
Edith Rivera and Hyman S. Trilling Professor and Chair of Molecular Biology and Microbiology, Tufts University

Dr. John Leong is the Edith Rieva and Hyman S. Trilling professor and chair of the Department of Molecular Biology and Microbiology at Tufts University School of Medicine. His general interest is in the interactions of bacterial pathogens and the host that lead to colonization, disease, and/or immune clearance. After earning his Ph.D. and M.D. from Brown University in 1987, Dr. Leong trained as a Helen Hay Whitney postdoctoral fellow with Dr. Ralph Isberg in the Department of Molecular Biology and Microbiology at Tufts. In 1990, he was recruited by Dr. Allen Steere to join the faculty of Tufts Medical Center where he began his studies of the Lyme disease bacterium that have continued since. He moved to the University of Massachusetts Medical School in 1995 and expanded his interests to include the food-borne pathogen enterohemorrhagic E. coli, where he developed a mouse model of infection that is used to investigate the pathogenesis of infection and the development of therapeutic interventions. He more recently initiated a research program focused on the respiratory pathogen Streptococcus pneumonia and why the elderly are particularly susceptible to this bacterium. Dr. Leong returned to Tufts to chair the Department of Molecular Biology and Microbiology in 2011. In 2018, Dr. Leong helped found the Stuart B. Levy Center for Integrative Management of Antimicrobial Resistance at Tufts University. Dr. Leong was a Pew Biomedical Scholar and an American Heart Association Established Investigator and is a Fellow of the American Academy of Microbiology.

Roger J. Lewis, M.D., Ph.D.
Professor, David Geffen School of Medicine, University of California Los Angeles

Dr. Lewis is currently a Professor at the David Geffen School of Medicine at UCLA, a Professor in the Department of Emergency Medicine at Harbor-UCLA Medical Center, and a member of the National Academy of Medicine. Dr. Lewis serves as a research mentor for numerous fellows and junior faculty and frequently lectures on the topics of clinical research design and the statistical analysis of clinical trials. In addition to his clinical teaching activities, Dr. Lewis participates in the design and implementation of numerous adaptive and platform clinical trials. He is a senior statistical reviewer for JAMA and co-edits the JAMA series Guides to Statistics and Methodology and the Senior Medical Scientist for Berry Consultants, LLC, a statistical consulting group that specializes in design and implementation of Bayesian adaptive clinical trials. He is a nationally recognized expert in the design of adaptive clinical trials—innovative designs that may be more efficient, safe, and ethical than traditional non-adaptive designs. He has chaired numerous data and safety monitoring boards for investigator-initiated, industry-sponsored, and federally-funded clinical trials. Dr. Lewis has served as a grant reviewer for the National Institutes of Health (NIH), the Agency for Healthcare Research and Quality (AHRQ), the Canadian Institutes of Health Research (CIHR), and foundations. He is a Past President of the Society for Academic Emergency Medicine (SAEM). Dr. Lewis has authored or coauthored over 250 original research publications, reviews, editorials, and chapters. His research interests include Bayesian and adaptive clinical trials; translational, clinical, health services and outcomes research; interim data analysis; the role and function of data monitoring committees; and difficulties surrounding informed consent in emergency research studies.

Avindra (Avi) Nath, M.D.
Senior Investigator and Clinical Director, Division of Neuroimmunology & Neurovirology, National Institute of Neurological Disorders and Stroke, NIH

Dr. Nath is the Clinical Director of the National Institute of Neurological Disorders and Stroke (NINDS) at NIH, where he is also Chief of the Section of Infections of the Nervous System, and Director of the Translational Center for Neurological Sciences. He specializes in neuro-immunology and neurovirology. His research is focused on

studying neuropathogenesis of emerging infections such as HIV infection, Ebola, Zika virus, and SARS-CoV-2 and conducts research on patients with undiagnosed neuroinflammatory disorders. He serves on advisory committees to the CDC, FDA, and WHO. He is the past President and the recipient of the Pioneer Award from the International Society of NeuroVirology and an award for scientific achievements by the World Federation of Neurology. He is an elected member of the Association of American Physicians and a Board member of the American Neurological Association. He was named in 2024 by TIME magazine amongst the 100 most influential people in health.

Rhisa Parera
Patient; Writer, Director, Producer, "Your Labs Are Normal"

Rhisa Parera was born and raised in New York City. She is 34 years old and has been dealing with Lyme disease since childhood. Though living a pretty much normal life, the disease eventually brought everything to a halt. That experience led her to produce a short film, that included friends and family reenacting her experience. She hopes that this film will help bring awareness to the severity of the disease and help patients get their quality of life back.

William (Bill) Robinson, M.D., Ph.D.
James W. Raitt, M.D. Professor of Medicine, Stanford University

The Robinson laboratory investigates the molecular mechanisms of autoimmune and rheumatic diseases, with a focus on rheumatoid arthritis and multiple sclerosis. The Robinson laboratory pioneered development of protein arrays and high-throughput sequencing approaches to identify the targets of antibody responses, investigate mechanisms underlying disease, and to develop novel therapeutic approaches. Dr. Robinson is using these technologies to define key roles for microbial triggers in the initial and progression of autoimmune diseases, including for EBV infection in multiple sclerosis and for oral bacterial mucosal breaks in rheumatoid arthritis.

Timothy Sellati, Ph.D.
Chief Scientific Officer, Global Lyme Alliance

As Chief Scientific Officer at Global Lyme Alliance (GLA), Dr. Sellati leads strategic planning and coordinates research initiatives to accelerate the development of more effective methods of diagnosis and treatment of Lyme and other tick-borne diseases. A noted immunologist and microbiologist, Dr. Sellati has 30 years of research experience in this area of vector-borne infectious diseases. He has published nearly 50 peer-reviewed infectious disease papers, almost half of which are focused on Lyme disease. Dr. Sellati is frequently invited to speak about his cutting-edge research at national and international scientific meetings and with news media outlets. Today he is considered one of the nation's foremost experts in the search to understand infectious disease processes and improve diagnosis and treatment for patients suffering from Lyme and other tick-borne illnesses. Dr. Sellati was the Immunology Scientific Councilor and is currently the Microbiology Councilor for the International Endotoxin and Innate Immunity Society, the past President of the Eastern New York Branch of the American Society for Microbiologists and has served as ad hoc member of a number of National Institutes of Health Study Section review panels and as a reviewer for several scientific journals in the areas of immunology and microbiology. Dr. Sellati also serves as a member of the New York State Lyme and Tick-Borne Disease Working Group, the Alabama Commission on Tick-Borne Illness, and serves as a subject matter expert and key opinion leader for diagnostics companies such as Quidel/Ortho and DiaSorin.

Leith States, M.D., M.P.H.
Chief Medical Officer, Office of Assistant Secretary for Health, Department of Health and Human Services

Dr. States serves as the Chief Medical Officer in the Office of the Assistant Secretary for Health (OASH) where he advises and supports the Assistant Secretary for Health (ASH) and other senior OASH leadership regarding

issues of national public health importance through collaboration with OASH program offices, the Department of Health and Human Services' (HHS) enterprise and interagency, and critical external stakeholders. The strength of these relationships is enhanced by data-driven evaluation to identify areas of greatest need in the support of developing the most impactful recommendations to the ASH and other senior leaders. Before being named to the permanent CMO role in OASH, Dr. States served as Deputy and Acting CMO from October 2018 to January 2020. During his time with OASH he has been fortunate to contribute to the development or advancement of initiatives concerning health equity (health equity in innovation for aging medically underserved populations, stigma reduction in persons living with HIV/AIDS (PLWHA), persons living with disabilities, persons with a history of substance use disorder), social determinants of health (Building a Healthier America initiative), and disparities reduction (Sickle Cell Disease in youth and hydroxyurea utilization, out-of-hospital cardiac arrest). Dr. States is board certified in Preventive Medicine, and is a current member of the American College of Preventive Medicine. He graduated with a Bachelor of Arts in Biochemistry from Azusa Pacific University in 2005 and received his Doctor of Medicine degree from the University of California at San Diego School of Medicine in 2010. In 2015, he completed his Master of Public Health Degree with a concentration in Population Health from Loma Linda University School of Public Health. He also graduated from the Loma Linda University Preventive Medicine residency that year, serving as Chief Resident in his final year of training. He is anticipated to complete his Master of Business from the George Washington University in the fall of 2021. His personal awards include the Meritorious Service Medal, Navy and Marine Corps Commendation Medal, Navy and Marine Corps Achievement Medal and multiple unit and campaign awards.

Matthew Tindall, M.B.A.
Co-Founder, President and Chief Executive Officer, Flightpath Biosciences

Matt has more than two decades of healthcare experience spanning general management, corporate development, strategy consulting, digital marketing and commercial operations. Matt was VP Marketing at Digitas Health New York, worked in strategic business development for Celera Genomics, led a cardiovascular business development team focused on the development of novel gene therapy, cell therapy and biomaterial products at Genzyme Corporation and co-founded and managed the start-up biopharmaceutical company Sarentis Therapeutics. In addition, his extensive entrepreneurial management experience also includes serving as CEO/Executive/Co-Founder of healthcare companies in the rare disease, oncology, pain, cardiovascular and genomics spaces with Fabric Genomics, Kodikaz, Wheatsheaf Group, IQVIA, Digitas Health, and Eli Lilly & Company. Mr. Tindall received his B.S. in Human Physiology from Lyman Brigg’s College at Michigan State University and his M.B.A. from the University of Texas at Austin.